Cargando…
Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
Omicron is currently the dominant SARS-CoV-2 variant and several sublineages have emerged. Questions remain about the impact of previous SARS-CoV-2 exposure on cross-variant immune responses elicited by the SARS-CoV-2 Omicron sublineage BA.2 compared to BA.1. Here we show that without previous histo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561373/ https://www.ncbi.nlm.nih.gov/pubmed/36267551 http://dx.doi.org/10.1016/j.isci.2022.105369 |
_version_ | 1784807938734424064 |
---|---|
author | Lee, Hye Kyung Knabl, Ludwig Walter, Mary Furth, Priscilla A. Hennighausen, Lothar |
author_facet | Lee, Hye Kyung Knabl, Ludwig Walter, Mary Furth, Priscilla A. Hennighausen, Lothar |
author_sort | Lee, Hye Kyung |
collection | PubMed |
description | Omicron is currently the dominant SARS-CoV-2 variant and several sublineages have emerged. Questions remain about the impact of previous SARS-CoV-2 exposure on cross-variant immune responses elicited by the SARS-CoV-2 Omicron sublineage BA.2 compared to BA.1. Here we show that without previous history of COVID-19, BA.2 infection induces a reduced immune response against all variants of concern (VOC) compared to BA.1 infection. The absence of ACE2 binding in sera of previously naïve BA.1 and BA.2 patients indicates a lack of meaningful neutralization. In contrast, anti-spike antibody levels and neutralizing activity greatly increased in the BA.1 and BA.2 patients with a previous history of COVID-19. Transcriptome analyses of peripheral immune cells showed significant differences in immune response and specific antibody generation between BA.1 and BA.2 patients as well as significant differences in the expression of specific immune genes. In summary, prior infection status significantly impacts the innate and adaptive immune response against VOC following BA.2 infection. |
format | Online Article Text |
id | pubmed-9561373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95613732022-10-16 Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients Lee, Hye Kyung Knabl, Ludwig Walter, Mary Furth, Priscilla A. Hennighausen, Lothar iScience Article Omicron is currently the dominant SARS-CoV-2 variant and several sublineages have emerged. Questions remain about the impact of previous SARS-CoV-2 exposure on cross-variant immune responses elicited by the SARS-CoV-2 Omicron sublineage BA.2 compared to BA.1. Here we show that without previous history of COVID-19, BA.2 infection induces a reduced immune response against all variants of concern (VOC) compared to BA.1 infection. The absence of ACE2 binding in sera of previously naïve BA.1 and BA.2 patients indicates a lack of meaningful neutralization. In contrast, anti-spike antibody levels and neutralizing activity greatly increased in the BA.1 and BA.2 patients with a previous history of COVID-19. Transcriptome analyses of peripheral immune cells showed significant differences in immune response and specific antibody generation between BA.1 and BA.2 patients as well as significant differences in the expression of specific immune genes. In summary, prior infection status significantly impacts the innate and adaptive immune response against VOC following BA.2 infection. Elsevier 2022-10-14 /pmc/articles/PMC9561373/ /pubmed/36267551 http://dx.doi.org/10.1016/j.isci.2022.105369 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Lee, Hye Kyung Knabl, Ludwig Walter, Mary Furth, Priscilla A. Hennighausen, Lothar Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients |
title | Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients |
title_full | Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients |
title_fullStr | Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients |
title_full_unstemmed | Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients |
title_short | Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients |
title_sort | limited cross-variant immune response from sars-cov-2 omicron ba.2 in naïve but not previously infected outpatients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561373/ https://www.ncbi.nlm.nih.gov/pubmed/36267551 http://dx.doi.org/10.1016/j.isci.2022.105369 |
work_keys_str_mv | AT leehyekyung limitedcrossvariantimmuneresponsefromsarscov2omicronba2innaivebutnotpreviouslyinfectedoutpatients AT knablludwig limitedcrossvariantimmuneresponsefromsarscov2omicronba2innaivebutnotpreviouslyinfectedoutpatients AT waltermary limitedcrossvariantimmuneresponsefromsarscov2omicronba2innaivebutnotpreviouslyinfectedoutpatients AT furthpriscillaa limitedcrossvariantimmuneresponsefromsarscov2omicronba2innaivebutnotpreviouslyinfectedoutpatients AT hennighausenlothar limitedcrossvariantimmuneresponsefromsarscov2omicronba2innaivebutnotpreviouslyinfectedoutpatients |